[6-K] ASCENTAGE PHARMA GROUP INTERNATIONAL Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Ascentage Pharma Group International filed a Form 6-K as a foreign private issuer to furnish a company press release. The filing notes that on November 19, 2025, the company issued a release titled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025.” The press release itself is attached as Exhibit 99.1 to the report. This Form 6-K does not present financial results or transaction details; it primarily serves to formally provide the investor conference announcement to the market.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On November 19, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report.

1

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title
99.1		Press Release dated November 19, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: November 19, 2025	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

FAQ

What did Ascentage Pharma (AAPG) file with the SEC?

Ascentage Pharma Group International filed a Form 6-K as a report of a foreign private issuer under the Securities Exchange Act of 1934.

What is the main purpose of this Ascentage Pharma (AAPG) Form 6-K?

The Form 6-K is used to furnish a press release issued on November 19, 2025, regarding Ascentage Pharma’s participation in upcoming investor conferences.

What does the attached press release for Ascentage Pharma (AAPG) cover?

The press release, titled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025,” discusses the company’s planned participation in three investor conferences.

Is financial or earnings information included in this Ascentage Pharma (AAPG) Form 6-K?

No financial results or earnings figures are presented; the Form 6-K mainly provides notice of the investor conference participation and furnishes the related press release as Exhibit 99.1.

Who signed the Ascentage Pharma (AAPG) Form 6-K?

The Form 6-K was signed on November 19, 2025, by Dajun Yang, who is identified as the company’s Chief Executive Officer.